UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 116

Sortiert nach

Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins

Oncogene, 2017-08, Vol.36 (35), p.4953-4962

2017

Volltextzugriff (PDF)

Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies

Journal of clinical oncology, 2005-09, Vol.23 (27), p.6719-6729

2005

Volltextzugriff (PDF)

Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia

The New England journal of medicine, 2001-07, Vol.345 (4), p.241-247

2001

Volltextzugriff (PDF)

In Vitro Antibody Evolution Targeting Germline Hot Spots to Increase Activity of an Anti-CD22 Immunotoxin

The Journal of biological chemistry, 2005-01, Vol.280 (1), p.607-617

2005

Volltextzugriff (PDF)

Immunotoxins in cancer therapy

Current Opinion in Immunology, 1999-10, Vol.11 (5), p.570-578

Kreitman, Robert J

1999

Volltextzugriff (PDF)

Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies

Journal of clinical oncology, 2000-04, Vol.18 (8), p.1622-1636

2000

Volltextzugriff (PDF)

Localization of mesothelin in epithelial ovarian cancer

Applied immunohistochemistry & molecular morphology, 2005-09, Vol.13 (3), p.243

2005

Volltextzugriff (PDF)

Improved Cytotoxic Activity toward Cell Lines and Fresh Leukemia Cells of a Mutant Anti-CD22 Immunotoxin Obtained by Antibody Phage Display

Clinical cancer research, 2002-04, Vol.8 (4), p.995-1002

2002

Volltextzugriff (PDF)

Intratumoral Administration of Recombinant Circularly Permuted Interleukin-4-Pseudomonas Exotoxin in Patients with High-Grade Glioma

Clinical cancer research, 2000-06, Vol.6 (6), p.2157-2165

2000

Volltextzugriff (PDF)

HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity

Clinical cancer research, 2005-02, Vol.11 (4), p.1545-1550

2005

Volltextzugriff (PDF)

Site-Specific Chemical Modification with Polyethylene Glycol of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) Improves Antitumor Activity and Reduces Animal Toxicity and Immunogenicity

Proceedings of the National Academy of Sciences - PNAS, 2000-07, Vol.97 (15), p.8548-8553

2000

Volltextzugriff (PDF)

Synaptic Integration Mediated by Striatal Cholinergic Interneurons in Basal Ganglia Function

Science (American Association for the Advancement of Science), 2000-07, Vol.289 (5479), p.633-637

2000

Volltextzugriff (PDF)

Targeted Toxins

Clinical cancer research, 2000-02, Vol.6 (2), p.326-334

2000

Volltextzugriff (PDF)

New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA

Clinical cancer research, 2005-08, Vol.11 (16), p.5840-5846

2005

Volltextzugriff (PDF)

Targeting of Interleukin-13 Receptor on Human Renal Cell Carcinoma Cells by a Recombinant Chimeric Protein Composed of Interleukin-13 and a Truncated Form of Pseudomonas Exotoxin A (PE38QQR)

Blood, 1996-05, Vol.87 (10), p.4333-4339

1996

Volltextzugriff (PDF)

Somatic hypermutation and VH gene usage in hairy cell leukaemia

British journal of haematology, 2006-06, Vol.133 (5), p.504-512

2006

Volltextzugriff (PDF)

Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma

Blood, 1994-01, Vol.83 (2), p.426-434

1994

Volltextzugriff (PDF)

Responses in Refractory Hairy Cell Leukemia to a Recombinant Immunotoxin

Blood, 1999-11, Vol.94 (10), p.3340-3348

1999

Volltextzugriff (PDF)

Ablation of Cerebellar Golgi Cells Disrupts Synaptic Integration Involving GABA Inhibition and NMDA Receptor Activation in Motor Coordination

Cell, 1998-10, Vol.95 (1), p.17-27

1998

Volltextzugriff (PDF)

Immunotoxins for targeted cancer therapy

Advanced drug delivery reviews, 1998-04, Vol.31 (1), p.53-88

1998

Volltextzugriff (PDF)

Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2

Journal of immunotherapy (1997), 2006-03, Vol.29 (2), p.208

2006

Volltextzugriff (PDF)

Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins

Blood, 2004-04, Vol.103 (7), p.2718-2726

2004

Volltextzugriff (PDF)

Accumulation of a recombinant immunotoxin in a tumor in vivo : Fewer than 1000 molecules per cell are sufficient for complete responses

Cancer research (Chicago, Ill.), 1998-03, Vol.58 (5), p.968-975

1998

Volltextzugriff (PDF)

Toxin-labeled monoclonal antibodies

Current pharmaceutical biotechnology, 2001-12, Vol.2 (4), p.313

Kreitman, R J

2001

Volltextzugriff (PDF)

Minimal Residual Disease in Hairy Cell Leukemia Patients Assessed by Clone-Specific Polymerase Chain Reaction

Clinical cancer research, 2006-05, Vol.12 (9), p.2804-2811

2006

Volltextzugriff (PDF)

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(115)
Mit Volltextzugriff
(111)

Publikationsform

Artikel
(116)

Sprache

Englisch
(116)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins

Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies

Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia

In Vitro Antibody Evolution Targeting Germline Hot Spots to Increase Activity of an Anti-CD22 Immunotoxin

Immunotoxins in cancer therapy

Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies

Localization of mesothelin in epithelial ovarian cancer

Improved Cytotoxic Activity toward Cell Lines and Fresh Leukemia Cells of a Mutant Anti-CD22 Immunotoxin Obtained by Antibody Phage Display

Intratumoral Administration of Recombinant Circularly Permuted Interleukin-4-Pseudomonas Exotoxin in Patients with High-Grade Glioma

HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity

Site-Specific Chemical Modification with Polyethylene Glycol of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) Improves Antitumor Activity and Reduces Animal Toxicity and Immunogenicity

Synaptic Integration Mediated by Striatal Cholinergic Interneurons in Basal Ganglia Function

Targeted Toxins

New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA

Targeting of Interleukin-13 Receptor on Human Renal Cell Carcinoma Cells by a Recombinant Chimeric Protein Composed of Interleukin-13 and a Truncated Form of Pseudomonas Exotoxin A (PE38QQR)

Somatic hypermutation and VH gene usage in hairy cell leukaemia

Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma

Responses in Refractory Hairy Cell Leukemia to a Recombinant Immunotoxin

Ablation of Cerebellar Golgi Cells Disrupts Synaptic Integration Involving GABA Inhibition and NMDA Receptor Activation in Motor Coordination

Immunotoxins for targeted cancer therapy

Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2

Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins

Accumulation of a recombinant immunotoxin in a tumor in vivo : Fewer than 1000 molecules per cell are sufficient for complete responses

Toxin-labeled monoclonal antibodies

Minimal Residual Disease in Hairy Cell Leukemia Patients Assessed by Clone-Specific Polymerase Chain Reaction

Suchergebnisse filtern